New board member
PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.
Helen works as an Investment manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process at Almi. Currently, she is the investment manager of four of Almi Invest South’s portfolio companies and a board member of two companies.
Helen has a PhD in Tumor Immunology and began her career as a translational cancer researcher. She has for several years worked with project management and network platforms for life science stakeholders from academia, industry and healthcare. Before joining Almi Invest, Helen was a Senior project manager at the Danish-Swedish cluster organization Medicon Valley Alliance and before that a Senior project manager at the science park Medicon Village.
PharmNovo is welcoming Helen to the team!
New board member
PharmNovo is pleased to announce that Helen Pettersson is now a member of the board, representing Almi Invest and Almi Invest Syd, being one of the larger investors in PharmNovo AB.
Helen works as an Investment manager at Almi Invest South. She focuses on Life Science and is responsible for the entire investment process at Almi. Currently, she is the investment manager of four of Almi Invest South’s portfolio companies and a board member of two companies.
Helen has a PhD in Tumor Immunology and began her career as a translational cancer researcher. She has for several years worked with project management and network platforms for life science stakeholders from academia, industry and healthcare. Before joining Almi Invest, Helen was a Senior project manager at the Danish-Swedish cluster organization Medicon Valley Alliance and before that a Senior project manager at the science park Medicon Village.
PharmNovo is welcoming Helen to the team!
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
